Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers by Jamois, Candice et al.
ORIGINAL ARTICLE
Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir
Coadministration in Healthy Volunteers
Candice Jamois, PharmD, Myriam Riek, MSc, and Christophe Schmitt, PharmD
F. Hoffmann-La Roche AG, Basel, Switzerland
DOI: 10.1111/j.1753-5174.2009.00016.x
ABSTRACT
Objective. This study was designed to investigate the pharmacokinetic effects of coadministration of saquinavir/
ritonavir with efavirenz at steady state.
Methods. Healthy volunteers in this open-label, two-arm, one-sequence, two-period crossover study (planned
enrollment of 40 participants) were randomized to one of two treatment arms: those in Arm 1 were scheduled to
receive saquinavir/ritonavir 1,000/100 mg orally twice daily for 29 days and efavirenz 600 mg orally once daily
starting on day 15 and continuing through day 29; participants randomized to Arm 2 were to receive efavirenz once
daily for 29 days and saquinavir/ritonavir 1,000/100 mg twice daily starting on day 15 through day 29. Assessments
included vital signs, laboratory analyses, electrocardiography, and blood levels of total saquinavir, ritonavir, and
efavirenz. Pharmacokinetic parameters included Cmax (maximum observed plasma concentration), tmax (time to reach
the maximum observed plasma concentration), t 1
2β (apparent elimination half-life), and AUC0-t (area-under-the-
plasma-concentration-time curve over one dosing interval).
Results. Eight participants (four in each arm) were enrolled; only two (one from each treatment arm) reached day
15 of the study and received the concurrent initial doses of saquinavir/ritonavir and efavirenz. The study was
terminated prematurely after these two participants experienced nonserious adverse events. The participant in Arm
1 experienced mild abdominal discomfort, diarrhea, sleep disorder, and headache and the participant in Arm 2
experienced moderate-intensity abdominal pain and mild vomiting with leukocytosis accompanied by elevated
pancreatic and hepatic enzymes (aspartate aminotransferase and alanine aminotransferase values of 2-fold and
3.5-fold the upper limit of normal, respectively). Both participants recovered completely following treatment
discontinuation. Only limited pharmacokinetic data were generated on these two participants.
Conclusions. The early termination of this study precluded drawing any deﬁnitive conclusions regarding the
pharmacokinetics at steady state of coadministered saquinavir/ritonavir and efavirenz.
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Introduction
E
favirenz (Sustiva
®; Bristol-Myers Squibb) is a
non-nucleoside reverse transcriptase inhibi-
tor, antiviral agent indicated for the treatment of
human immunodeﬁciency virus-1 (HIV-1) infec-
tion. Because of its prolonged half-life (40 to 55
hours), efavirenz can be dosed once daily [1].
Efavirenz is also a potent inducer of the cyto-
chrome P4503A4 isoenzyme (CYP3A4) [1], the
isoenzyme that metabolizes the protease inhibitor
antivirals. When efavirenz is coadministered with
the protease inhibitors, a profound reduction in
protease inhibitor exposure results [1,2].
Saquinavir (Invirase
®; Hoffmann-La Roche) is a
potent HIV protease inhibitor with oral bioavail-
ability limited by extensive ﬁrst-pass metabolism
mediated primarily by CYP3A4. While saquinavir
1
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enhancedwhencombinedwithalow(subtherapeu-
tic) dose of ritonavir [4], a potent inhibitor of
CYP3A4 [5]. Thus, increasing the plasma concen-
trations of saquinavir by combining it with low-
dose ritonavir may compensate for the acceleration
of its metabolism by efavirenz.
Few studies have evaluated the pharmacoki-
netics of saquinavir/ritonavir and efavirenz when
coadministered. In one study of healthy partici-
pants, no signiﬁcant differences in plasma concen-
trations of saquinavir were observed following
once-daily administration of saquinavir 1,600 mg/
ritonavir 200 mg when administered after a
2-week run-in period with efavirenz 600 mg or
when efavirenz was added following a 2-week
run-in period with saquinavir/ritonavir [6]. Similar
results were reported when efavirenz 600 mg was
added once daily after 10-day administration of
saquinavir 400 mg/ritonavir 400 mg twice daily in
healthy volunteers [7].
In an open-label efﬁcacy study of 32 efavirenz-
naive, protease inhibitor-experienced, HIV-in-
fected patients who received efavirenz in combina-
tionwithatwice-dailyboostedregimen(saquinavir
1,000 mg/ritonavir100 mg)for6months,theredid
not appear to be any clinically relevant alterations
in plasma levels of saquinavir resulting from the
combination (levels of other agents were not mea-
sured), although these values ranged widely [8].
Another similarly designed study evaluated the
pharmacokinetics of the three agents in 42 HIV-
infected patients who were switched from their
current regimen to a once-daily boosted regimen
(saquinavir 1,200 mg/ritonavir 100 mg) plus
efavirenz due to adverse events [9]. As in the pre-
vious study, a large interpatient variability in
saquinavir and efavirenz pharmacokinetics was
noted, although the plasma levels of both of these
agents were adequate to maintain virologic sup-
pression[9].Becauseonlylimiteddataareavailable
to support the use of saquinavir/ritonavir with
efavirenz,thepresentstudywasdesignedtofurther
investigate the pharmacokinetic effects of coad-
ministration of all three drugs at steady state.
Methods
Study Design
This open-label, randomized, two-arm, one-se-
quence, two-period crossover study in healthy
volunteers was conducted at the Roche Clinical
Pharmacology Unit in Strasbourg, France. The
overall study design is shown in Figure 1. An
enrollment of 40 participants (20 for each treat-
ment arm) was planned. The study was conducted
in full conformance with the principles of the Dec-
laration of Helsinki or with the laws and regula-
tions of the country in which the research was
conducted, whichever provided participants with
the greatest protection. Written informed consent
was obtained from all participants before any
screening procedures were performed.
Study Participants
Healthymalesorfemalesaged18to65yearswitha
body-mass index of 18 to 30 kg/m
2 were eligible if
on screening they had a clinically normal physical
examination and laboratory tests and no prior
history of: (i) clinically signiﬁcant gastrointestinal,
renal, hepatic, bronchopulmonary, neurological,
cardiovascular, or endocrinologic disease; (ii) gen-
eralized drug reaction, including severe allergic
asthma, regional or generalized urticaria, or ana-
phylaxis of any cause; or (iii) any major illness
within 4 weeks prior to screening. Females were
excluded if they were pregnant, breast-feeding, or
using hormone replacement therapy. Females of
childbearing potential were required to use effec-
tive nonhormonal contraception during the study
and for at least 1 month after the last dose. Use of
anyCYP3A4inhibitororinducerwithin4weeksor
any other medication (except aspirin or acetamin-
ophen, allowed up to 48 hours of dosing) within 2
weeks prior to the ﬁrst dose of study drug or within
six times the elimination half-life (whichever was
longer)wasprohibited.Participantsweretoabstain
from ingesting grapefruit/grapefruit juice within
14 days and any herbal product containing Saint
John’s wort or garlic within 4 weeks from dosing
andfromusingtobaccoforaminimumof6months
prior to the start of the study. In addition, partici-
pants were excluded if they had a positive test for
drugs of abuse in their urine or a positive alcohol
breath test at screening or baseline; had a history of
alcohol and/or drug abuse; had a positive test for
HIV or hepatitis B or C at screening; had partici-
patedinaclinicalstudywithaninvestigationaldrug
within 3 months prior to dosing; and/or had
donated or experienced blood loss of more than
400 mL in the 3-month period prior to dosing.
StudyTreatment
Participants randomized to Arm 1 received sa-
quinavir/ritonavir 1,000/100 mg orally twice daily
(morning and evening doses at 12-hour intervals)
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and continuing through day 29, these participants
also received efavirenz 600 mg orally once daily at
bedtime (approximately 10:00 pm). Participants
randomized to Arm 2 received efavirenz once
daily at bedtime for 29 days and saquinavir/
ritonavir 1,000/100 mg twice daily (at 12-hour
intervals) starting on day 15 through day 29. To
ensure that steady-state blood levels were reached
for both saquinavir and ritonavir, the combination
was administered for 14 days. This duration, al-
though longer than required based on the half-
lives of the individual drugs, was selected because
ritonavir is not only a potent inhibitor of CYP3A
but also increases the enzyme activity of CYP3A
(inhibition-associated induction) [5]. Due to this
autoinduction,plasmaconcentrationsofsaquinavir
and ritonavir generally reach steady state 2 weeks
afterthestartofritonaviradministration.Toensure
that maximal induction potential was achieved,
efavirenz also was administered for 14 days.
Randomization numbers were generated by the
sponsor and allocated by the Unit’s pharmacist
sequentially in the order in which participants
were screened and enrolled. On day 15, no
morning doses of either agent were given.
Saquinavir/ritonavir was administered concur-
rently with meals (which were standardized to fat
content in the study unit) and approximately 2
hours prior to efavirenz administration.
Clinical and Pharmacokinetic Assessments
Participants were required to stay at the study
center the night prior to study initiation, on days
11,13,14,15,16,21,26,29,andatfollow-up.Vital
signs were taken, and electrocardiography and
clinical laboratory tests (hematology, biochemistry,
and urinalysis) were performed at least weekly. All
adverse events reported during the study were
recorded and graded as to intensity. Participants
presenting conﬁrmed values of hepatic laboratory
tests of more than three times the upper limit of
Study
Day
Day 1 to 14 Day 15 to 29
Within 15 to
21 days after
last dose
Arm 1 14 days of dosing with
saquinavira/
ritonavir
14 days of dosing with 
saquinavir/ritonavira 
and efavirenzb 
Day 44 to 50
No. completing 14
days treatment = 1 
No. withdrawn
during 14 days
treatment = 3 
No. withdrawn 
during 29 days 
treatment = 1  
No. completing 29 
days treatment = 0 
A2
Total withdrawn 
during each 
treatment period = 4
Arm 2 Day 44 to 50
14 days of dosing
with efavirenzb
14 days of dosing with 
efavirenzb and 
saquinavir/ritonavira 
No. completing 14
days treatment = 1 
No. completing 29 
days treatment = 0 
No. withdrawn
during 14 days
treatment = 3 
No. withdrawn 
during 29 days 
treatment = 1 
No. receiving at least
one dose = 4 
No. participants
randomized = 4 
Day -28 to -2
evening
Day -2 evening
to Day -1
No. receiving at least
one dose = 4 
No. participants
randomized = 4 
Total withdrawn
during each 
treatment period = 4
Screening Treatment Period Baseline Follow-Up
Figure 1 Study design and patient disposition.
aSaquinavir/ritonavir 1,000/100 mg doses every 12 hours (1 hour). On Day
15, only the evening dose was administered.
bEfavirenz 600 mg every 24 hours at bedtime.
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clinicalsigns,weretobewithdrawnfromthestudy.
Ifmorethan2subjectsinonearmpresentedsevere
signs of toxicity (grade 3/4) or other safety con-
cerns of the same kind/same organ system for
which relationship to the study drugs was consid-
ered possible or probable, the discontinuation of
thestudyarmcouldbedecided.Discontinuationof
the other study arm could also be discussed
between the investigator and the clinical pharma-
cology scientist.
Blood levels of total saquinavir and ritonavir
were determined in Arm 1 and of efavirenz in Arm
2 on days 14 and 29 at predose and 0.5, 1, 2, 3, 4, 5,
6,8,10,12,14(16forefavirenz),and24hoursafter
the evening/bedtime dose of saquinavir/ritonavir
or efavirenz. Blood levels of efavirenz in Arm 1 and
of saquinavir and ritonavir in Arm 2 were also
measured on day 29 at predose and at 4 hours after
the evening dose. Additional blood levels were
drawn before the evening/bedtime doses on days
11, 12, and 13 and on days 26, 27, and 28.
The following pharmacokinetic parameters
were estimated using standard noncompartmental
methods: Cmax (maximum observed plasma con-
centration), tmax (time to reach the maximum
observed plasma concentration), t1
2β (apparent
elimination half-life), and AUC0-t (area-under-
the-plasma-concentration-time curve over one
dosing interval). In addition, trough plasma con-
centrations were estimated prior to the evening
dose on days 11, 12, 13, 14, 16, 27, 28, and 29. The
study was designed to include additional pharma-
cokinetic assessments at day 29; these were not
performed due to the premature termination of
the study.
Plasma samples were analyzed for saquinavir
and ritonavir by Pharma Bio-Research Group
BV (Assen, the Netherlands) and for efavirenz by
BAS Analytics (Stareton, United Kingdom) using
validated, speciﬁc, high-performance liquid
chromatography/mass spectroscopy/mass spec-
troscopy methods. The lower limit of quantiﬁca-
tion was 1 ng/mL for saquinavir and ritonavir and
200 ng/mL for efavirenz.
Results
A total of eight participants (four in each arm),
aged 26 to 45 years, of whom two were females and
seven were Caucasian, were enrolled. Two partici-
pants only (one from each treatment arm) reached
day 15 of the study and received the initial doses
of the combination of saquinavir/ritonavir and
efavirenz. The investigator together with the
sponsor terminated the study prematurely after
these two participants experienced nonserious
adverse events, with the remaining participants in
Arm 1 receiving 4, 9, and 14 days of saquinavir/
ritonavir and those in Arm 2 receiving 3, 8, and 10
days of efavirenz (see Figure 1 for the disposition
of the participants). One participant from Arm 2
developed a maculopapular rash on day 9 of treat-
ment with efavirenz and withdrew from the study
for this reason.
Adverse events reported by the participant
from Arm 1 who received the combination of
saquinavir/ritonavir and efavirenz included mild
abdominal discomfort, diarrhea, sleep disorder,
and headache. The study drug was discontinued
and all symptoms resolved without treatment. The
majority of laboratory test results remained within
normal ranges, including liver function tests, pan-
creatic enzymes, and leukocyte count and differ-
ential. Elevated total cholesterol (5.70 mmol/L;
grade 2) and triglyceride (6.27 mmol/L; grade 3)
levels on day 16 normalized by day 17. Five hours
after coadministration of saquinavir/ritonavir and
efavirenz on the evening of day 15, the partici-
pant from Arm 2 experienced moderate-intensity
abdominal pain and mild vomiting. Laboratory
tests showed leukocytosis with neutrophilia
accompanied by elevated pancreatic and hepatic
enzymes and serum triglyceride levels. Aspartate
aminotransferase levels were 77 IU/L (grade 1;
2-fold the ULN) on day 17 and alanine ami-
notransferase levels were 145 IU/L (grade 2; 3.5-
fold the ULN) on day 18. The study drug was
discontinued and the clinical symptoms were
resolved without treatment on day 16. All labora-
tory abnormalities normalized by day 19 except
for the alanine aminotransferase elevation, which
declined to normal by day 29. Although the
adverse events in these participants were nonseri-
ous, these elevations appeared similar in nature to
the hepatotoxicity reported in a separate clinical
study involving saquinavir/ritonavir and rifampin,
another potent inducer of CYP3A4 [10].
All four participants in Arm 1 and three of four
participants in Arm 2 reported at least one adverse
event. Most of the reported events were mild in
intensity, and none were reported to be severe. In
addition to the adverse events described above,
those considered to be probably related to study
treatment were: maculopapular rash in one addi-
tional participant during treatment with efavirenz
and sleep disorder in one participant during treat-
ment with efavirenz. No participant experienced a
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study, and no clinically signiﬁcant physical abnor-
malities were observed.
Pharmacokinetic Analysis
Limited pharmacokinetic data were available from
blood level data taken from three participants prior
to the termination of the study. Scheduled blood
samples for trough plasma level determinations
were collected from two participants in Arm 1 and
from one participant in Arm 2 (Table 1). The indi-
vidual plasma concentration-time curves for all
three agents are presented in Figure 2a, b. Com-
plete steady-state pharmacokinetic proﬁles (day
14) were available for only one participant in each
arm (Table 2). Pharmacokinetic proﬁles were not
obtainableforthetwoparticipantswhoreceivedall
three agents; only sparse blood samples were taken
Table 1 Individual trough plasma concentrations, ng/mL
Day 11 Day 12 Day 13
Saquinavir
Arm 1, participant 2 337 640 867
Arm 1, participant 4 602 700 1,220
Ritonavir
Arm 1, participant 2 57.8 83.8 86.2
Arm 1, participant 4 137 163 251
Efavirenz
Arm 2, participant 1 1,080 1,050 1,060
0
1000
2000
3000
4000
5000
240 260 280 300 320 340 360 380
Time (hr)
Efavirenz
Ritonavir
Saquinavir
ARM=ARM 1, SUBJECT=2
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
/
m
L
)
0
1000
2000
3000
4000
5000
240 260 280 300 320 340 360 380
Time (hr)
ARM=ARM 2, SUBJECT=1
Efavirenz
Ritonavir
Saquinavir
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
/
m
L
)
a
b
Figure 2 (a) Plasma concentration-time curves for participant 2, Arm 1. Saquinavir/ritonavir trough concentrations on days
11 to 13 and full pharmacokinetic (PK) proﬁle on day 14 (312 to 336 hours). Sparse plasma concentrations from samples
taken after initiation of triple-combination therapy are also shown. (b) Plasma concentration-time curves for participant 1,Arm
2. Efavirenz trough concentrations on days 11 to 13 and full PK proﬁle on day 14 (312 to 336 hours). Sparse plasma
concentrations from samples taken after initiation of triple-combination therapy are also shown.
Table 2 Pharmacokinetic parameters at steady state in
the two participants experiencing toxicity
Participant
Treatment Arm Drug
Cmax
(ng/mL)
tmax
(h)
AUCo-t
(ng*h/mL)
t 1
2β
(h)
Arm 2, participant 1 Efavirenz 4,780 2.00 42,523 26.5
Arm 1, participant 2 Ritonavir 1,270 1.00 5,512 3.53
Arm 1, participant 2 Saquinavir 3,570 2.00 19,640 5.98
t, Twenty-four hours for efavirenz and 12 hours for saquinavir/ritonavir.
AUCo-t=area-under-the-plasma-concentration-time curve over one dosing
interval; Cmax = maximum observed plasma concentration; tmax = time to reach
the maximum observed plasma concentration; t 1
2β = apparent elimination
half-life.
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ticipants withdrew from the study on day 15.
However, the plasma concentrations of saquinavir,
ritonavir, and efavirenz determined in these
samples were similar to concentrations observed
during the administration of saquinavir/ritonavir
and efavirenz alone in these participants
(Figure 2a, b).
Discussion
The hepatic and gastrointestinal adverse events
identiﬁed in two participants in this study were
unanticipated based on previously reported studies
in which saquinavir/ritonavir and efavirenz were
coadministered in healthy participants or in HIV-
infected patients, although safety data are limited
[6–9]. Commonly reported adverse events have
included dizziness [6,7] and headache [6], and no
clinically relevant alterations in laboratory param-
eters were reported in the majority of studies [6–8]
although one HIV-infected patient with chronic
hepatitis B and C had liver enzyme elevations due
to hepatitis reactivation [9]. In a study involving 11
HIV-infected patients on a regimen of saquinavir
1,000 mg/ritonavir 200 mg twice daily in combi-
nation with efavirenz 600 mg once daily, one
patient developed grade 4 hepatotoxicity; therapy
was successfully resumed with lower doses of
ritonavir (100 mg) and efavirenz (400 mg) [11]. A
review of the Roche Drug Safety database for
adverse events associated with the use of
saquinavir/ritonavir with efavirenz compared to
saquinavir/ritonavir without efavirenz revealed too
few cases on the triple combination, precluding a
meaningful analysis.
Although this study permitted only limited
pharmacokinetic analysis, the single participant
receiving 2 weeks of treatment with efavirenz
600 mg once daily had pharmacokinetic param-
eters within previously reported ranges for HIV-
infected individuals receiving efavirenz alone [12]
or in combination with saquinavir [9]. Similarly,
the pharmacokinetic parameters in the participant
receiving saquinavir/ritonavir for 2 weeks were
in agreement with those previously reported
in healthy volunteers [13] or in HIV-infected
patients receiving concurrent efavirenz [9].
However, due to the early termination of this
study, these data are too limited to allow deﬁnitive
conclusions regarding the pharmacokinetics at
steady state of coadministered saquinavir/ritonavir
and efavirenz.
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